Camlin Fine Sciences Limited (CAMLINFINE) AI Stock Analysis

Camlin Fine Sciences Limited

(NSE:CAMLINFINE)

Select Model

Rating:42Neutral

Price Target:INR 81.00▼(-3.63% Downside)

Action:reiterated

Date:08/18/26

The score is held down primarily by weak financial quality (sharp FY2026 revenue contraction, compressed margins, and especially inconsistent/negative free cash flow) and bearish technicals (price below major moving averages and negative MACD). Valuation further pressures the score due to an extremely high P/E, with no dividend yield data to offset it.

Positive Factors

Specialty ingredient platformA broad specialty-ingredient portfolio serves multiple end markets and addresses product shelf-life, stability, and performance needs. This application-driven B2B model can support recurring customer demand and reduce reliance on any single industry over the next several quarters.

Negative Factors

Sharp revenue contractionThe steep FY2026 revenue decline points to a significant deterioration in demand, volumes, mix, or execution and weakens the earnings base supporting the business. A smaller revenue platform can also reduce operating leverage and make recovery in profitability more difficult over coming quarters.

Camlin Fine Sciences Limited (CAMLINFINE) vs. iShares MSCI India ETF (INDA)

Market Cap: INR 16.16B
Dividend Yield: ―
Average Volume (3M): 61.85K
Price to Earnings (P/E): 323.5
Beta (1Y): 0.86
Revenue Growth: 8.40%
EPS Growth: ―
Country: India
Employees: 624
Sector: General
Sector Strength: 55
Industry: Chemicals - Specialty

Camlin Fine Sciences Limited Business Overview & Revenue Model

Company Description

Camlin Fine Sciences Limited, an India-based company headquartered in Mumbai and established in 1931 (originally as Camlin Fine Chemicals Limited until August 2011), is involved in the global research, development, production, and distribution of a d...

How the Company Makes Money

Camlin Fine Sciences primarily makes money by manufacturing and selling specialty ingredient chemicals and ingredient blends to business customers (B2B). Its main revenue stream is product sales from its ingredient portfolio—particularly antioxidants...

Camlin Fine Sciences Limited Financial Statement Overview

Summary

Financial performance is mixed but constrained by weak and inconsistent fundamentals. Income statement trends are volatile with a sharp FY2026 revenue decline (-44.8%), meaningfully compressed margins (EBITDA margin ~5.5%, net margin ~1.6%), and only a recent return to profitability after FY2024–FY2025 losses. The balance sheet is improved with lower leverage (debt-to-equity ~0.69x in FY2026), but cash flow quality is the biggest issue: free cash flow is negative in FY2026 and FY2025 and cash conversion is weak despite positive net income.

Income Statement

43Neutral

Balance Sheet

58Neutral

Cash Flow

34Negative

Financial statement breakdown
Breakdown	TTM	Mar 2026	Mar 2025	Mar 2024	Mar 2023	Mar 2022
Income Statement
Total Revenue	18.62B	17.23B	16.67B	15.95B	16.82B	14.04B
Gross Profit	5.83B	4.86B	7.78B	6.58B	8.41B	6.34B
EBITDA	833.43M	954.20M	1.92B	487.60M	1.84B	1.79B
Net Income	58.82M	276.27M	-1.39B	-927.53M	521.06M	606.78M
Balance Sheet
Total Assets	0	23.24B	20.24B	19.52B	20.60B	18.00B
Cash, Cash Equivalents and Short-Term Investments	1.09B	1.53B	1.92B	812.28M	951.90M	1.29B
Total Debt	0	7.20B	6.81B	6.83B	8.01B	6.46B
Total Liabilities	-10.01B	13.23B	11.49B	10.95B	12.36B	10.35B
Stockholders Equity	10.01B	10.41B	9.02B	8.65B	8.19B	7.48B
Cash Flow
Free Cash Flow	374.83M	-330.85M	-157.24M	784.06M	-934.11M	-683.40M
Operating Cash Flow	671.39M	244.81M	267.23M	1.39B	508.98M	1.45B
Investing Cash Flow	-160.19M	-559.23M	-753.50M	-664.98M	-1.25B	-2.49B
Financing Cash Flow	-677.54M	359.26M	724.43M	-859.72M	596.58M	1.36B

Camlin Fine Sciences Limited Technical Analysis

Technical Analysis SentimentNegative

Last Price84.05

Price Trends

50DMA96.19Negative

100DMA112.11Negative

200DMA122.15Negative

Market Momentum

MACD-4.11Positive

RSI38.41Neutral

STOCH24.14Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For IN:CAMLINFINE, the sentiment is Negative. The current price of 84.05 is below the 20-day moving average (MA) of 88.29, below the 50-day MA of 96.19, and below the 200-day MA of 122.15, indicating a bearish trend. The MACD of -4.11 indicates Positive momentum. The RSI at 38.41 is Neutral, neither overbought nor oversold. The STOCH value of 24.14 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for IN:CAMLINFINE.

Camlin Fine Sciences Limited Peers Comparison

Overall Rating

UnderperformOutperform

Sector (55)

Financial Indicators

IN:CAMLINFINE against its peers
Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
IN:KIRIINDUS	77Outperform	INR 35.17B	0.56	―	―	10.71%	2756.39%
IN:GOCLCORP	73Outperform	INR 15.30B	4.17	―	9.71%	-95.58%	-72.91%
IN:FCL	69Neutral	INR 56.58B	40.33	―	0.27%	91.44%	19.67%
IN:NOCIL	67Neutral	INR 22.92B	34.63	―	1.09%	0.96%	-28.98%
IN:ROSSARI	65Neutral	INR 22.12B	14.48	―	0.13%	19.76%	11.74%
Sector *	55Neutral	$6.65B	3.83	-15.92%	6.20%	10.91%	7.18%
IN:CAMLINFINE	42Neutral	INR 16.15B	323.46	―	―	8.40%	―

* General Sector Average

Performance Comparison

IN:CAMLINFINE and its peers over the selected period
Ticker	Company Name	Price	Change	% Change
IN:CAMLINFINE	Camlin Fine Sciences Limited	84.05	-115.70	-57.92%
IN:FCL	Fineotex Chemical Limited	48.59	16.55	51.67%
IN:GOCLCORP	GOCL Corporation Limited	308.65	-22.93	-6.91%
IN:KIRIINDUS	Kiri Industries Limited	539.70	-6.25	-1.14%
IN:NOCIL	NOCIL Limited	137.20	-42.32	-23.58%
IN:ROSSARI	Rossari Biotech Ltd	399.25	-242.58	-37.79%

Camlin Fine Sciences Limited Corporate Events

Camlin Fine Sciences Independent Director Pradip Kanakia Completes Board Tenure

Oct 18, 2026

Camlin Fine Sciences Limited has announced that independent director Pradip Kanakia has completed his five-year term on the board and ceased to hold office effective October 18, 2026. The board has formally recorded its appreciation for his guidance...

Glossary

BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.

Date of analysis: Aug 18, 2026

Camlin Fine Sciences Limited AI Stock Analysis